Commercial Credit Report for Stella Pharma Corp

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Stella Pharma Corp is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Stella Pharma Corp
3-2-7, Koraibashi, Chuo-ku
Phone: +81 647071516p:+81 647071516	OSAKA-SHI, OSK 541-0043 Japan	Ticker: 48884888

Business Summary

Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (a particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.

(Source: N-30D)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	3/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
8731	Commercial physical and biological research
8071	Medical laboratories

Officers and Directors

Title	Name	Age	Title Date	Start Date
Chairman of the Board, Chief Executive Officer, Representative Director	TomoyukiAsano	51	6/1/2020	6/1/2007
President, Chief Operating Officer, Representative Director	KokiUehara	46	6/1/2020	4/1/2012
Executive Officer, Director of General Affairs	HirotakaOgawa
6 additional Officers and Directors records available in full report.

General Information

Number of Employees:	46	(As of 3/31/2023)
Outstanding Shares:	31,225,441	(As of 12/31/2023)
Shareholders:	9,945
Stock Exchange:	TYO
Fax Number:	+81 647072077

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN